High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer

Cancer‐associated fibroblasts (CAFs) regulate tumour growth, metastasis and response to treatment. Recent studies indicate the existence of functionally distinct CAF subsets. Suggested mechanisms whereby CAFs can impact on treatment response include paracrine signalling affecting cancer cell drug se...

Full description

Saved in:
Bibliographic Details
Published in:The journal of pathology. Clinical research 2017-01, Vol.3 (1), p.38-43
Main Authors: Paulsson, Janna, Rydén, Lisa, Strell, Carina, Frings, Oliver, Tobin, Nicholas P, Fornander, Tommy, Bergh, Jonas, Landberg, Göran, Stål, Olle, Östman, Arne
Format: Article
Language:English
Subjects:
adjuvant
Biomarkers
Breast cancer
Cancer and Oncology
Cancer och onkologi
Cancer therapies
Chemotherapy
Clinical Medicine
Data collection
Fibroblasts
growth-factor
inhibition
Klinisk medicin
Medical and Health Sciences
Medicin och hälsovetenskap
Metastases
Original
Paracrine signalling
PDGFR beta
PDGFRβ
Radiation therapy
receptor expression
resistance
sensitivity
Studies
Tamoxifen
term-follow-up
tumor microenvironment
Tumors
tumour stroma
Writing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer‐associated fibroblasts (CAFs) regulate tumour growth, metastasis and response to treatment. Recent studies indicate the existence of functionally distinct CAF subsets. Suggested mechanisms whereby CAFs can impact on treatment response include paracrine signalling affecting cancer cell drug sensitivity and effects on tumour drug uptake. PDGFRβ is an important regulator of fibroblasts. Experimental studies have linked PDGFRβ‐positive fibroblasts to metastasis and also to reduced tumour drug uptake. This study has investigated the potential role of PDGFRβ‐positive fibroblasts in response to adjuvant tamoxifen treatment of breast cancer. Analyses of two breast cancer collections from randomised studies analysing adjuvant tamoxifen treatment in early breast cancer demonstrated significant benefit of tamoxifen in the group with low stromal PDGFRβ, which was not observed in the group with high stromal PDGFRβ. In general terms these findings provide novel evidence, derived from analyses of randomised clinical studies, of response‐predictive capacity of a marker‐defined subset of CAFs and, more specifically, identify stromal PDGFRβ as a marker related to tamoxifen benefit in early breast cancer.
ISSN:2056-4538
2056-4538
DOI:10.1002/cjp2.56